Electrical muscle stimulation intervention study with Japanese elderly with sarcopenia or dynapenia: randomized-controlled trial

Electrical muscle stimulation intervention study with Japanese elderly with sarcopenia or dynapenia: randomized-controlled trial - Electrical muscle stimulation intervention study with Japanese elderly with sarcopenia or dynapenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052995

Enrollment

Registered

2024-01-08

Start date

2024-01-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia or presarcopenia or dynapenia

Interventions

Electrical muscle stimulation (-) 16 weeks Protein (-) 16 weeks Electrical muscle stimulation (+) 16 weeks Protein (-) 16 weeks Electrical muscle stimulation (+) 16 weeks Protein (+) 16 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sarcopenia - Physical performance (gait speed<1.0 m/s or five-time chair stand test>=12 s or short physical performance battery<=9) - Skeletal muscle index (male<7.0 kg/m2, female<5.7 kg/m2) or presarcopenia - Physical performance (gait speed>=1.0 m/s or five-time chair stand test<12 s or short physical performance battery>9) - Skeletal muscle index (male<7.0 kg/m2, female<5.7 kg/m2) or dynapenia - Physical performance (gait speed<1.0 m/s or five-time chair stand test>=12 s or short physical performance battery<=9) - Skeletal muscle index (male>=7.0 kg/m2, female>=5.7 kg/m2)

Exclusion criteria

Exclusion criteria: - Those who have electronic substances such as pacemakers and heart-lung machines in their bodies - Those who have heart disease - Those who have metal plates on their stomachs or thighs - Those who cannot take protein

Design outcomes

Primary

Measure	Time frame
After 8- and 16-week intervention Physical performance (gait speed, five-time chair stand test, short physical performance battery)	—

Secondary

Measure	Time frame
After 8- and 16-week intervention Muscle mass Muscle quality (phase angle) Muscle strength (hand grip) Cognitive function Depression score Quality of life Autonomic nervous function Height Knee osteoarthritis function Blood pressure Arterial sclerosis Urinary incontinence Blood factors	—

Countries

Japan

Contacts

Public ContactShu Nishikori

POLA CHEMICAL INDUSTRIES, INC. FRONTIER RESEARCH CENTER

s-nishikori@pola.co.jp045-826-7134

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026